Alto Neuroscience, Inc. ANRO · Stock Open Alto Neuroscience, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Alto Neuroscience, Inc. Analysis (ANRO)
Is Alto Neuroscience, Inc. a good investment? Alto Neuroscience, Inc. (ANRO) is currently trading at 23.30 USD. Market analysts have a consensus price target of 38.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Alto Neuroscience, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -3.19.
Investor FAQ
Does Alto Neuroscience, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Alto Neuroscience, Inc.?
Alto Neuroscience, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -2.31.
Company Profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Community Discussion